These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 30547371)

  • 61. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.
    McGlinchey AJ; Govaere O; Geng D; Ratziu V; Allison M; Bousier J; Petta S; de Oliviera C; Bugianesi E; Schattenberg JM; Daly AK; Hyötyläinen T; Anstee QM; Orešič M
    JHEP Rep; 2022 May; 4(5):100477. PubMed ID: 35434590
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Non-alcoholic fatty liver disease: a survey of involvement of primary care physicians.
    Mari A; Omari S; Abu Baker F; Abu Much S; Said Ahmad H; Khoury T; Nseir W; Mahamid M
    Minerva Gastroenterol Dietol; 2019 Dec; 65(4):255-258. PubMed ID: 31646850
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Non-Alcoholic Fatty Liver Disease].
    Brůha R
    Vnitr Lek; 2019; 65(9):571-575. PubMed ID: 31635468
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Epidemiology and disease burden of non-alcoholic steatohepatitis in greater China: a systematic review.
    Zou H; Ge Y; Lei Q; Ung COL; Ruan Z; Lai Y; Yao D; Hu H
    Hepatol Int; 2022 Feb; 16(1):27-37. PubMed ID: 35098442
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis.
    Quek J; Chan KE; Wong ZY; Tan C; Tan B; Lim WH; Tan DJH; Tang ASP; Tay P; Xiao J; Yong JN; Zeng RW; Chew NWS; Nah B; Kulkarni A; Siddiqui MS; Dan YY; Wong VW; Sanyal AJ; Noureddin M; Muthiah M; Ng CH
    Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):20-30. PubMed ID: 36400097
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Evidence of bias during liver transplant evaluation of non-alcoholic steatohepatitis cirrhosis patients.
    Danford CJ; Iriana S; Shen C; Curry MP; Lai M
    Liver Int; 2019 Jun; 39(6):1165-1173. PubMed ID: 30809932
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Epidemiology of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Japan: A focused literature review.
    Eguchi Y; Wong G; Lee EI; Akhtar O; Lopes R; Sumida Y
    JGH Open; 2020 Oct; 4(5):808-817. PubMed ID: 33102749
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe.
    Lazarus JV; Ekstedt M; Marchesini G; Mullen J; Novak K; Pericàs JM; Roel E; Romero-Gómez M; Ratziu V; Tacke F; Cortez-Pinto H; Anstee QM;
    J Hepatol; 2020 Jan; 72(1):14-24. PubMed ID: 31518646
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Serum C16:1n7/C16:0 ratio as a diagnostic marker for non-alcoholic steatohepatitis.
    Yamada K; Mizukoshi E; Seike T; Horii R; Terashima T; Iida N; Kitahara M; Sunagozaka H; Arai K; Yamashita T; Honda M; Takamura T; Harada K; Kaneko S
    J Gastroenterol Hepatol; 2019 Oct; 34(10):1829-1835. PubMed ID: 30864239
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Evaluation of emerging NASH therapies: the impact of treatment efficacy profiles on long-term health outcomes.
    Herring WL; Gould IG; Wittrup-Jensen V; Ertle J; Kuti E; Wolowacz S
    J Comp Eff Res; 2022 Dec; 11(18):1349-1363. PubMed ID: 36317935
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Development and validation of a novel non-invasive test for diagnosing fibrotic non-alcoholic steatohepatitis in patients with biopsy-proven non-alcoholic fatty liver disease.
    Gao F; Huang JF; Zheng KI; Pan XY; Ma HL; Liu WY; Byrne CD; Targher G; Li YY; Chen YP; Chan WK; Zheng MH
    J Gastroenterol Hepatol; 2020 Oct; 35(10):1804-1812. PubMed ID: 32246876
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Systematic Literature Review and Critical Appraisal of Health Economic Models Used in Cost-Effectiveness Analyses in Non-Alcoholic Steatohepatitis: Potential for Improvements.
    Johansen P; Howard D; Bishop R; Moreno SI; Buchholtz K
    Pharmacoeconomics; 2020 May; 38(5):485-497. PubMed ID: 31919793
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Prospective comparison of transient elastography, MRI and serum scores for grading steatosis and detecting non-alcoholic steatohepatitis in bariatric surgery candidates.
    Garteiser P; Castera L; Coupaye M; Doblas S; Calabrese D; Dioguardi Burgio M; Ledoux S; Bedossa P; Esposito-Farèse M; Msika S; Van Beers BE; Jouët P
    JHEP Rep; 2021 Dec; 3(6):100381. PubMed ID: 34786549
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Prevalence of prediabetes and diabetes in children and adolescents with biopsy-proven non-alcoholic fatty liver disease.
    Nobili V; Mantovani A; Cianfarani S; Alisi A; Mosca A; Sartorelli MR; Maffeis C; Loomba R; Byrne CD; Targher G
    J Hepatol; 2019 Oct; 71(4):802-810. PubMed ID: 31279904
    [TBL] [Abstract][Full Text] [Related]  

  • 75. CD44 is a key player in non-alcoholic steatohepatitis.
    Patouraux S; Rousseau D; Bonnafous S; Lebeaupin C; Luci C; Canivet CM; Schneck AS; Bertola A; Saint-Paul MC; Iannelli A; Gugenheim J; Anty R; Tran A; Bailly-Maitre B; Gual P
    J Hepatol; 2017 Aug; 67(2):328-338. PubMed ID: 28323124
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Nonalcoholic steatohepatitis medical patient journey from the perspective of hepatologists, gastroenterologists and patients: a cross-sectional survey.
    Rinella M; Cryer DR; Articolo A; Fisher T; Schneider J; Nadolsky K
    BMC Gastroenterol; 2022 Jul; 22(1):335. PubMed ID: 35811319
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study.
    Loomba R; Lawitz EJ; Frias JP; Ortiz-Lasanta G; Johansson L; Franey BB; Morrow L; Rosenstock M; Hartsfield CL; Chen CY; Tseng L; Charlton RW; Mansbach H; Margalit M
    Lancet Gastroenterol Hepatol; 2023 Feb; 8(2):120-132. PubMed ID: 36521501
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis (NASH) in the United Kingdom (UK) in 2018.
    Morgan A; Hartmanis S; Tsochatzis E; Newsome PN; Ryder SD; Elliott R; Floros L; Hall R; Higgins V; Stanley G; Cure S; Vasudevan S; Pezzullo L
    Eur J Health Econ; 2021 Jun; 22(4):505-518. PubMed ID: 33751289
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Non-invasive diagnosis and monitoring of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
    Tincopa MA; Loomba R
    Lancet Gastroenterol Hepatol; 2023 Jul; 8(7):660-670. PubMed ID: 37060912
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The different expression of tumor suppressors, RASSF1A, RUNX3, and GSTP1, in patients with alcoholic steatohepatitis (ASH) vs non-alcoholic steatohepatitis (NASH).
    Jia Y; Ji P; French B; Tillman B; French SW
    Exp Mol Pathol; 2019 Jun; 108():156-163. PubMed ID: 30951700
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.